Pre-treatment with ETAR and ETBR receptors antagonists interferes with fibroblast growth, suggesting that such effect is the direct consequence of the inhibition of the paracrine release of ET-1 by tumor cells [61]. The gene discussed is EDN1; the disease is neoplasm.